Tailoring the Interface with a Multifunctional Ligand for Highly Efficient and Stable FAPbI 3 Perovskite Solar Cells and Modules.
Fuqiang LiXiaofeng HuangChaoqun MaJunpeng XueYing LiDanbi KimHyun-Seock YangYuanyuan ZhangBo Ram LeeJunghwan KimBinghui WuSung Heum ParkPublished in: Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Perovskite solar cells (PeSCs) using FAPbI 3 perovskite films often exhibit unfavorable phase transitions and defect-induced nonradiative interfacial recombination, resulting in considerable energy loss and impairing the performance of PeSCs in terms of efficiency, stability, and hysteresis. In this work, a facile interface engineering strategy to control the surface structure and energy-level alignment of perovskite films by tailoring the interface between the FAPbI 3 film and hole-transporting layer using 4-hydroxypicolinic acid (4HPA) is reported. According to density functional theory studies, 4HPA has prominent electron delocalization distribution properties that enable it to anchor to the perovskite film surface and facilitate charge transfer at the interface. By enabling multiple bonding interactions with the perovskite layer, including hydrogen bonds, PbO, and PbN dative bonds, 4HPA passivation significantly reduces the trap density and efficiently suppresses nonradiative recombination. The obtained perovskite films exhibit superior optoelectronic properties with improved crystallinity, pure α-phase FAPbI 3 , and favorable energy band bending. Following this strategy, 4HPA post-treatment PeSCs achieve a champion power conversion efficiency of 23.28% in 0.12 cm 2 cells and 19.26% in 36 cm 2 modules with excellent environmental and thermal stabilities.
Keyphrases
- room temperature
- perovskite solar cells
- highly efficient
- density functional theory
- solar cells
- ionic liquid
- high efficiency
- heavy metals
- dna damage
- molecular dynamics
- induced apoptosis
- dna repair
- drug delivery
- risk assessment
- signaling pathway
- reduced graphene oxide
- cell cycle arrest
- cancer therapy
- aqueous solution
- replacement therapy
- diabetic rats
- case control